Concepedia

Publication | Open Access

Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines

DOIFull Paper Access

45

Citations

16

References

2022

Year

Natalia Abraham, Sarah Spruin, Tanya Rossi, Bruce Fireman, Joseline Zafack, Christine Blaser, Amanda Shaw, Kimberley Hutchings, Susanna Ogunnaike-Cooke
Vaccine

Abstract

The risk of myocarditis and/or pericarditis is higher after mRNA-1723 vaccination than BNT162b2 vaccination in those aged 18-39 years, especially in males aged 18-29 years, where the risk is several times higher.

References

YearCitations

Page 1